LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

A. Hollebecque, Mitesh J. Borad, Lipika Goyal, A. Schram, J.O. Park, P.A. Cassier, Suneel D. Kamath, D.T. Wai Meng, E. Dotan, R. Kim, V. Sahai, D-Y. Oh, C-Y. Liao, M. Millward, D. Roda Perez, C. Ferté, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley